RESUMEN
ABSTRACT: A 58-year-old man with dysphagia and trismus symptoms presented a lobulated tumor in the right tonsil and ipsilateral laterocervical stony adenopathies in the physical examination. He had prostate carcinoma as clinical precedent. The tonsilar lesion showed focal FDG uptake (SUV max , 10.89) on PET/CT and increased glycemic metabolism in the left sacral wing (SUV max , 10.90) without clear morphological lesion in CT. There was also uptake of the tracer in sacrum in the bone scan. Metastatic involvement was suspected, requiring radioguided biopsy to determine the etiology. Due to radioguided biopsy, histological analysis of the metastasis was performed, with epidermoid carcinoma metastasis diagnosis.
Asunto(s)
Cámaras gamma , Sacro , Humanos , Masculino , Persona de Mediana Edad , Biopsia Guiada por Imagen/instrumentación , Tomografía Computarizada por Tomografía de Emisión de Positrones , Sacro/diagnóstico por imagen , Sacro/patologíaRESUMEN
Introducción y objetivo:Los subtipos histológicos agresivos de cáncer de tiroides son menos frecuentes y tienen peor pronóstico que los bien diferenciados (CDT). Los subtipos agresivos más importantes son el carcinoma de células de Hürthle (CCH), el carcinoma anaplásico y el pobremente diferenciadoEn esta revisión vamos a hablar del papel del PET-CT, especialmente con 18F-FDG, en estas estirpes histológicas agresivas, así como en subtipos agresivos de CDT (células altas, esclerosante difuso ) y en el carcinoma de tiroides refractario al radioyodo.Síntesis:Aunque la principal indicación del PET con 18F-FDG en el cáncer de tiroides es la sospecha de recidiva, en pacientes con CDT con tiroglobulina sérica elevada y rastreo corporal total (RCT) con radioyodo negativo, esta técnica tiene crecientes aplicaciones en el CDT.Así mismo, el PET con 18F-FDG también es una herramienta diagnóstica eficiente en el estudio del carcinoma anaplásico, el pobremente diferenciado y otras estirpes histológicas agresivas.Es recomendado en las guías clínicas actuales como parte de la estadificación inicial en cánceres de tiroides anaplásico, pobremente diferenciados y CCH invasivo. Y cada vez se emplea más en otras indicaciones como valoración pronóstica, de la respuesta al tratamiento, e incluso durante el seguimiento de pacientes de alto riesgo.El empleo de otros trazadores para PET como el 68Ga-PSMA y el 68Ga-DOTATATE no han demostrado claramente su beneficio clínico frente a la 18F-FDG. Suelen limitarse a casos en los que sea necesaria la valoración de la densidad de receptores de análogos de somatostatina y PSMA previa a terapia metabólica. (AU)
Introduction and objective: The aggressive histological subtypes of thyroid cancer are less common and have a worse prognosis than well differentiated ones (DTC). The most important aggressive subtypes are Hürtle cell carcinoma (CHH), anaplasic and poorly differentiated carcinoma. In this review, we are going to evaluate the role of PET-CT, especially with 18F-FDG, in these aggressive histological lines, as well as in aggressive subtypes of DTC (tall cells, diffuse sclerosing...) and in radioiodine-refractory differentiated thyroid carcinoma. Synthesis: Although the main indication for 18F-FDG PET in thyroid cancer is suspected recurrence, in patients with DTC with elevated serum thyroglobulin and radioiodine-negative whole-body scan (WBS), this technique has increasing applications in DTC. Likewise, 18F-FDG PET is also an efficient diagnostic tool in the study of anaplastic carcinoma, poorly differentiated and other aggressive lines. It is recommended, in current clinical guidelines, as part of the initial staging in anaplastic, poorly differentiated, and invasive HCC. And it is increasingly used in other indications such as prognostic assessment, evaluation of treatment response, and even during the follow-up of high-risk patients. The use of other PET tracers, such as 68Ga-PSMA and 68Ga-DOTATATE have not clearly demonstrated their clini-cal benefit over 18F-FDG. They are usually limited to cases in which it is necessary to assess the density of somatostatin analogs and PSMA receptors prior to metabolic therapy. Conclusions: 18F-FDG PET-CT is the most effective functional diagnostic technique in the study of poorly differentiated and aggressive thyroid neoplasms, since they show little or no avidity for radioiodine and however high affinity for 18F-FDG. The role of other PET tracers for the evaluation of these tumors is promising, although it still needs studies with a larger number of patients. (AU)
Asunto(s)
Neoplasias de la Tiroides , Carcinoma , Terapéutica , Pacientes , PronósticoRESUMEN
No disponible